Elekta (EKTA) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
29 Apr, 2026Executive summary
Net sales at constant exchange rates grew by 2% year-over-year, driven by strong order intake and commercial momentum in Europe and China, while reported sales in SEK declined by 10% due to currency effects.
Book-to-bill ratio improved to 1.17 for Q3, reflecting robust order growth in China, the U.S., and Europe.
Significant restructuring underway, with SEK 417 million charge in Q3 and over 80% of planned changes executed; annual cost savings expected to exceed SEK 500 million with full impact from Q1 next year.
Product launches, notably Elekta Evo with U.S. approval in January, supported margin improvement and commercial execution.
Net income dropped to SEK 12 million (from SEK 336 million), with EPS at SEK 0.03 (from SEK 0.89), impacted by restructuring charges and FX.
Financial highlights
Net sales increased by 2% year-over-year in constant currency, reaching SEK 4,239 million; solution sales up 1%, service up 3%.
Adjusted gross margin improved to 38.3% (from 37.1%), despite negative impacts from tariffs (100 bps) and FX (130 bps).
EBIT margin at 11.9% (up from 11.7%); adjusted EBIT was SEK 504 million.
Cash flow after continuous investments was SEK 255 million for Q3, with year-to-date improvement of SEK 443 million; net debt decreased to SEK 3,819 million.
Adjusted EPS was SEK 0.88 (down from SEK 0.94 year-over-year).
Outlook and guidance
Full-year 2025/26 outlook reiterated: net sales in constant currency expected to grow year-over-year.
Continued negative impact from FX and tariffs anticipated in Q4 and beyond.
Midterm targets confirmed, including gross margin returning to pre-pandemic levels and EBIT margin reaching 14% or higher.
Guidance for China: double-digit growth (~10%) in both orders and revenue for H2.
Full run-rate cost savings from restructuring expected in Q1 2026/27.
Latest events from Elekta
- Margin expansion, software growth, and asset-light upgrades drive sustainable, profitable growth.EKTA
Investor update9 Jul 2026 - AI-driven adaptive radiotherapy and unified software drive adoption, margin, and upgrade growth.EKTA
Investor update8 Jul 2026 - Order growth, margin gains, and record cash flow offset US and China weakness; guidance lowered.EKTA
Q3 24/258 Jul 2026 - Profitable growth and margin expansion achieved despite Q4 sales decline and inflation.EKTA
Q4 23/248 Jul 2026 - Sales and margins declined, but new products and cost savings support H2 growth outlook.EKTA
Q2 24/258 Jul 2026 - Q4 margin hit a five-year high, but R&D impairment led to a net loss; outlook remains strong.EKTA
Q4 24/258 Jul 2026 - Turnaround plan targets mid-single digit sales growth and 14–16% EBIT margin by FY28/29.EKTA
CMD 202618 Jun 2026 - Profitability and cash flow surged on cost savings, despite SEK sales decline and impairments.EKTA
Q4 25/261 Jun 2026 - Four strategic priorities and a new model target SEK 500M+ savings and global growth.EKTA
Strategy update9 Apr 2026